Stock Comparison

LLY vs TWST

Eli Lilly and Co vs Twist Bioscience Corp

The Verdict

TWST takes this one.

LLY

Eli Lilly and Co

0.5

out of 10

Distressed

Winner

TWST

Twist Bioscience Corp

7.5

out of 10

Solid Pick

Head-to-Head

$965.0B

Market Cap

$2.9B

52.6

P/E Ratio

N/A

Profit Margin

-19.6%

N/A

Return on Equity

-16.6%

N/A

Debt-to-Equity

0.2

Moderate

Overall Risk

Aggressive

0.5

DVR Score

7.5

The Deep Dive

LLY0.5/10

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Full LLY Analysis

TWST7.5/10

Twist Bioscience (TWST) continues to be a high-risk, high-reward investment with significant 10x growth potential within 3-5 years. The company's unique silicon-based DNA synthesis platform maintains its position for future market leadership in synthetic biology and DNA data storage. Recent Q1 fiscal 2026 results showed robust revenue growth (17% YoY), an improved gross margin (52.0%), and narrowe...

Full TWST Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.